Phaseline

Companies › Chimeric Therapeutics

Chimeric Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CHM-2101
Cadherin 17 (CDH17) chimeric antigen receptor (CAR) T cell therapy
CDH17Phase 1Neuroendocrine TumorsDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06055439CHM-2101Phase 1Neuroendocrine TumorsOncologyDec 2026

Targets

CDH17 (1)

Companies with the same targets

SOTIO Biotech

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.